ABT.SW Abbott Laboratories (SIX) at CHF100.00 pre-earnings: watch 22 Jan for guidance
ABT.SW stock trades at CHF100.00 on the SIX market on 19 Jan 2026 as investors prepare for Abbott Laboratories’ earnings on 22 Jan 2026. The company reports with a trailing EPS 6.32 and PE 15.82, leaving room for reaction if diagnostics or devices miss or beat estimates. We focus on near-term catalysts, valuation vs the healthcare sector, and what a single beat or miss could mean for intraday trading and short-term targets.
Earnings calendar and catalysts: ABT.SW stock
Abbott Laboratories (ABT.SW) will report results on 22 Jan 2026. Investors will watch diagnostic volume, medical devices sales, and margin commentary. A strong diagnostics read could lift near-term revenues, while weakness in structural heart or diabetes devices would pressure guidance. Consensus estimates are not published here, so traders should monitor the official release and live guidance on revenue and EPS.
Financials and valuation: ABT.SW stock analysis
At CHF100.00 ABT.SW shows a PE 15.82 and dividend yield 1.94%. Trailing free cash flow per share is 3.95, and return on equity is 28.24%. Price averages are 50-day 99.24 and 200-day 102.26, so the stock sits near short-term average. Compared with the healthcare sector average PE 33.73, ABT.SW trades at a discount, reflecting steady cash flow but modest growth expectations.
Meyka AI rates ABT.SW with score and technicals: ABT.SW stock
Meyka AI rates ABT.SW with a score out of 100: 71.99 / 100 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. Technicals show RSI 39.74 and a close near the 50-day average. Volume is light today at 40.00 shares traded, so intraday moves may amplify on the earnings print. These grades are not guaranteed and are not financial advice.
Price targets and forecast: ABT.SW stock forecast
Meyka AI’s forecast model projects a quarterly price of CHF110.78 and a yearly price of CHF91.69. Versus the current CHF100.00, the quarterly projection implies +10.78% upside and the yearly projection implies -8.31% downside. Monthly projection is CHF98.19 (-1.81%). Forecasts are model-based projections and not guarantees. Traders should use these as scenario markers, not strict targets.
Risks and opportunities: ABT.SW stock outlook
Opportunity: valuation gap to sector gives upside if growth accelerates in diagnostics and devices. Risk: post-pandemic diagnostic demand normalization and regulatory or reimbursement pressure. Currency and US revenue exposure matter for Swiss-listed ABT.SW in CHF. Watch margin guidance and reorder patterns after earnings to gauge medium-term momentum.
Final Thoughts
ABT.SW stock sits at CHF100.00 on 19 Jan 2026 with earnings due on 22 Jan 2026, making this an earnings-driven intraday story. The company shows solid cash generation (free cash flow per share 3.95) and a conservative payout (payout ratio 28.93%), while valuation at PE 15.82 is below the healthcare sector average 33.73. Meyka AI rates ABT.SW 71.99 / 100, B+ (BUY) based on multi-factor analysis including sector and growth metrics. Our model projects a quarterly price target CHF110.78 (+10.78%) and a yearly price CHF91.69 (-8.31%) versus the current price. Use the quarterly projection as an upside scenario and the yearly projection as a conservative reversion guide. Keep position sizes modest ahead of the release, monitor trading volume spikes, and treat model forecasts as probabilistic scenarios. Meyka AI provides this AI-powered market analysis to guide preparation; forecasts are model-based projections and not guarantees.
FAQs
When does Abbott (ABT.SW) report earnings and why does it matter?
Abbott (ABT.SW) reports on 22 Jan 2026. The result matters because diagnostics and device segment guidance can move the stock intraday. Expect reactions to revenue, EPS, and forward commentary that affect short-term trading and price discovery.
What are the key valuation metrics for ABT.SW stock?
ABT.SW trades at PE 15.82 with EPS 6.32 and dividend yield 1.94%. Free cash flow per share is 3.95 and ROE is 28.24%, showing cash strength and efficient capital returns versus peers.
What does Meyka AI forecast for ABT.SW stock after earnings?
Meyka AI’s forecast model projects CHF110.78 for the quarter and CHF91.69 for the year. Versus CHF100.00, that implies +10.78% and -8.31% respectively. Forecasts are model-based projections and not guarantees.
How should traders position for ABT.SW earnings intraday?
Keep positions size-limited, set clear stop levels, and watch volume for confirmation. A surprise beat may push price above the 50-day average 99.24, while a miss could test the 200-day 102.26 or lower. Trade plans should reflect volatility risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
